Non alcoholic fatty liver disease: A new risk factor for cardiovascular disease?;La stéatose hépatique non alcoolique: Un nouveau facteur de risque cardio-vasculaire?

Tunisie Medicale

Volumn 91, Issue 3, 2013, Pages 171-174

  Sdiri, Wissem ^a   Romdhane, Hayfa ^b   Mbarek, Dorra ^a   Ben Abdallah, Hatem ^b   Longo, Selma ^a   Abdelli, Mohamed Nabil ^b   Boujnah, Mohamed Rachid ^a  

^a MONGI SLIM HOSPITAL   (Tunisia)

^b MILITARY HOSPITAL OF TUNIS   (Tunisia)

Author keywords

Cardiovascular risk; Hepatic steatosis; Metabolic syndrome; Non alcoholic fatty liver disease

Indexed keywords

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; EVALUATION; HUMAN; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PATHOPHYSIOLOGY; REVIEW; SYSTEMATIC REVIEW;

CARDIOVASCULAR DISEASES; FATTY LIVER; HUMANS; RISK FACTORS;

EID: 84876925941     PISSN: 00414131     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Lemoine M. Stéatopathie métabolique: définition et histoire biologique. Gastroenterol Clin Biol 2009; 33:398-404.
2. Loria P, Lonardo A, Bellentani S, Day CP, Marchesini G, Carulli N. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question. Nutr Metab Cardiovasc Dis. 2007; 17:684-698.
3. Targher G, Arcaro G. Nonalcoholic fatty liver disease and increased risk of cardiovascular disease. Artherosclerosis 2007;191: 235-240.
4. JAY SIWEK, MARGARET L. GOURLAY, David C et al. How to write an Evidence-Based Clinical Review Article. Am Fam Physician. 2002; 65:251-258.
5. O'Leary DH, Polak JF, Kronmal RA et al. Distribution and correlates of sonographically detected carotid artery disease in the cardiovascular health study. The CHS collaborative research group. Stroke 1992;23:1752-1760.
6. Targher G, Bertolini L, Padovani R et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes care 2006;29:1325-1330.
7. Villanova N, Moscatiello S, Ramilli S et al. Endothelial dysfunction and cardiovascular risk profile in non-alcoholic fatty liver disease. Hepatology 2005;42: 473-478.
8. Targher G, Bertolini L, Padovani R et al. Increased prevalence of cardiovascular disease among type 2 diabetic patients with nonalcoholic fatty liver disease. Diabet Med 2006; 23: 403-409.
9. Lin YC, Lo HM, Chen JD. Sonographic fatty liver, overweight and ischaemic heart disease. World J Gastroenterol 2005;11: 4838-4842.
10. Kessler A, Levy Y, Roth A. et al. Increased prevalence of NAFLD in patients with acute myocardial infarction independent of BMI. Hepatology 2005;42;623A [Abstract]
11. Schwimmer JB, Deutsch R, Behling C, Lavine JE. Fatty liver as a determinant of atherosclerosis. Hepatology 2005;42:610A [Abstract]
12. Adams LA, Lymp JF, St Sauver J et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-121.
13. Wannawethee G, Ebrahim S, Shaper AG. Gamma-glutamyl transferase: determinants and association with mortality from ischaemic heart disease and all causes. Am J epidemiol 1995;142: 699-708.
14. Ioannou GN, Weiss NS, Boyko EJ, Mozaffarian D, Lee SP. Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology 2006;43:1145-1151.
15. Ruttmann E, Brant LJ, Concin H et al. Gamma-glutamyl transferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a chort of 163 944 austrian adults. Circulation 2005;112:2130-2137.
16. Yki-Jarvinen H, Westerbacka J. The fatty liver and insulin resistance. Curr Mol Med 2005;5:287-295.
17. Nannipieri M, Gonzales C, Baldi S et al. Liver enzymes, the metabolic syndrome and incident diabetes. The Mexico city diabetes study. Diabetes care 2005;28:1757-1762.
18. Targher G, Bertolini L, Scala L et al. Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non diabetic men. Role of visceral adipose tissue. Diabetes Med 2005;22:1354-1358.
19. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb vasc biol. 2004; 24:29-33.
20. Targher G, Bertolini L, Zenari L. Hypoadiponectinemia is closely associated with non-alcoholic hepatic steatosis in obese subjects. Diabetes care 2004; 27: 2085-2086.
21. Charlton M, Sreekumar R, Rasmusserm D, Lindor K, Nair KS. Alpolipoprotein synthesis in non-alcoholic steatohepatitis. Hepatology 2002;35:898-904.
22. Loria P, Adinolfi LE, Bellantini S et al. Practice guidelines for the diagnosis and management of non-alcoholic fatty liver disease. A Decalogue from the Italian association for the study of the liver (AISF) expert committee. Dig Liver Dis 2010;42:272-282.